TFF PHARMACEUTICALS, INC. (TFFP): Price and Financial Metrics

TFF PHARMACEUTICALS, INC. (TFFP): $5.90

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add TFFP to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#307 of 389

in industry

TFFP Price/Volume Stats

Current price $5.90 52-week high $23.00
Prev. close $5.90 52-week low $4.55
Day low $5.71 Volume 12,100
Day high $6.00 Avg. volume 14,649
50-day MA $6.41 Dividend yield N/A
200-day MA $8.97 Market Cap 13.95M

TFFP Stock Price Chart Interactive Chart >

TFFP Stock Summary

  • As for revenue growth, note that TFFP's revenue has grown 378.06% over the past 12 months; that beats the revenue growth of 98.44% of US companies in our set.
  • In terms of volatility of its share price, TFFP is more volatile than 99.85% of stocks we're observing.
  • TFF PHARMACEUTICALS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -103.63%, greater than the shareholder yield of just 4.12% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to TFF PHARMACEUTICALS INC are CYN, RYTM, ASTC, TDUP, and SAGE.
  • Visit TFFP's SEC page to see the company's official filings. To visit the company's web site, go to www.tffpharma.com.

TFFP Valuation Summary

  • TFFP's price/earnings ratio is -0.7; this is 102.4% lower than that of the median Healthcare stock.
  • TFFP's price/earnings ratio has moved up 19.1 over the prior 51 months.

Below are key valuation metrics over time for TFFP.

Stock Date P/S P/B P/E EV/EBIT
TFFP 2023-12-29 17.8 1.2 -0.7 -0.3
TFFP 2023-12-28 19.0 1.3 -0.7 -0.3
TFFP 2023-12-27 16.8 1.1 -0.7 -0.3
TFFP 2023-12-26 17.8 1.2 -0.7 -0.3
TFFP 2023-12-22 18.7 1.3 -0.7 -0.3
TFFP 2023-12-21 17.3 1.2 -0.7 -0.3

TFFP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TFFP has a Quality Grade of D, ranking ahead of 8.49% of graded US stocks.
  • TFFP's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows TFFP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.001 1 -13.217
2021-03-31 0.001 1 -26.319
2020-12-31 0.000 NA -46.985
2020-09-30 0.000 NA -310.219
2020-06-30 0.000 NA 41.705
2019-12-31 0.000 NA 70.796

TFFP Price Target

For more insight on analysts targets of TFFP, see our TFFP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.00 Average Broker Recommendation 1.5 (Moderate Buy)

TFF PHARMACEUTICALS, INC. (TFFP) Company Bio


TFF Pharmaceuticals, Inc. operates as an early-stage biopharmaceutical company. The Company develops powder and molecule drugs for the treatment of chronic respiratory diseases and lung conditions. TFF Pharmaceuticals serves clients in the State of Texas.


TFFP Latest News Stream


Event/Time News Detail
Loading, please wait...

TFFP Latest Social Stream


Loading social stream, please wait...

View Full TFFP Social Stream

Latest TFFP News From Around the Web

Below are the latest news stories about TFF PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TFFP as an investment opportunity.

TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations due to an adverse event (AE) Successful transition of all four patients from oral tacrolimus to TFF TAC, leading to significant lowering of tacrolimus blood levels with no clinical evidence of acute r

Yahoo | December 19, 2023

TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ETFORT WORTH, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company will hold a conference call and webcast to review initial data from the ongoing Phase 2 trials of TFF VORI and

Yahoo | December 18, 2023

TFF Pharmaceuticals Announces Reverse Stock Split

Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023FORT WORTH, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. T

Yahoo | December 15, 2023

TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. “I am pleased to welcome Thomas King to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceu

Yahoo | December 13, 2023

TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors

FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Michael Patane, Ph.D., to its Board of Directors. “I am pleased to welcome Dr. Patane to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Ph

Yahoo | November 30, 2023

Read More 'TFFP' Stories Here

TFFP Price Returns

1-mo 17.25%
3-mo -22.62%
6-mo -37.10%
1-year -70.98%
3-year -98.37%
5-year N/A
YTD -15.95%
2023 -73.26%
2022 -88.16%
2021 -38.06%
2020 167.66%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!